Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
FKD Therapies Oy Identifier:
First received: September 6, 2012
Last updated: February 6, 2014
Last verified: February 2014

This Phase 2 study is designed to assess the efficacy and safety of INSTILADRIN (rAd-IFN with Syn3) when given intravesically to patients with high grade non-muscle invasive bladder cancer who are refractory to or have relapsed from BCG therapy. The pharmacodynamics of INSTILADRIN will also be studied by measuring the interferon (IFNα2b) levels excreted in the urine. rAd-IFN is a non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the interferon alpha-2b (IFNα2b) gene. Syn 3 is clinical surfactant excipient which enhances the ability of the adenoviral vector to transfect cells in the bladder wall.

Condition Intervention Phase
Superficial Bladder Cancer
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)

Resource links provided by NLM:

Further study details as provided by FKD Therapies Oy:

Primary Outcome Measures:
  • To evaluate the incidence of high grade-recurrence free survival following up to 4 instillations of INSTILADRIN [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate the safety of rAd-IFN/Syn3 instillation as assessed by NCI-CTCAE V4.03 [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • To evaluate the incidence of high grade-recurrence-free survival at 3, 6 and 9 months. [ Time Frame: 3, 6, and 9 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: September 2012
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rAd-IFN Dose 1x10^11vps/ml
Subjects will be randomly assigned to one of two INSTILADRIN arms.
The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
Other Name: rAd-IFN
Experimental: rAd-IFN dose 3x10^11 vps/ml
Subjects will be randomly assigned to one of two INSTILADRIN arms.
The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
Other Name: rAd-IFN

Detailed Description:

Criteria for Evaluation:

Efficacy: A Response is defined as no evidence of recurrence of a high grade tumor by cystoscopy, cytology or if clinically indicated, biopsy.

Safety: The safety and tolerability of INSTILADRIN will be evaluated based on adverse event reports, vital signs, ECGs, clinical laboratory values and results of physical examination.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Aged 18 years or older at the time of consent
  2. Able to give informed consent
  3. Subjects with high grade BCG-refractory or relapsed NMIBC including

    • High grade non-invasive papillary carcinomas (Ta) and subjects with high grade tumors that invade sub-epithelial connective tissue (T1) or
    • Carcinoma in situ (CIS) only or
    • CIS and Ta or T1 tumors Refractory is defined as failure to achieve a disease-free state at six months after adequate induction of BCG therapy with either maintenance or re-induction at 3 months. Adequate induction is defined as a minimum of 5 out of 6 induction doses and adequate maintenance is defined as a minimum of 2 out of 3 doses of treatment.

    Relapse is defined as recurrence within 1 year after a complete response to BCG treatment

  4. Complete resection of visible papillary lesions or CIS by TURBT or endoscopic resection between 14 and 60 days prior to beginning study treatment
  5. Available for the whole duration of the study
  6. Life expectancy >2 years, in the opinion of the investigator
  7. ECOG status 2 or less
  8. Absence of upper tract urothelial carcinoma
  9. Female subjects of childbearing potential must use maximally effective birth control during the period of therapy, must be willing to use contraception for 1 month following the last study drug infusion and must have a negative urine or serum pregnancy test upon entry into this study. Otherwise, female subjects must be postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile.
  10. Male subjects must be surgically sterile or willing to use a double barrier contraception method upon enrollment, during the course of the study, and for 1 month following the last study drug infusion.
  11. Adequate laboratory values.

    • Hemoglobin ≥10 g/dL.
    • WBC ≥4000/μL.
    • ANC ≥2000/μL.
    • Platelet count ≥100,000/μL.
    • INR within institutional normal limits.
    • aPTT within institutional normal limits.
    • AST ≤1.5 x ULN.
    • ALT ≤1.5 x ULN.
    • Total bilirubin within institutional normal limits.
    • Creatinine ≤1.5 x ULN.

Exclusion Criteria:

  1. Current or previous evidence of muscle invasive or metastatic disease
  2. Current systemic therapy for bladder cancer
  3. Current or prior pelvic external beam radiotherapy
  4. Prior treatment with adenovirus-based drugs
  5. Suspected hypersensitivity to interferon alpha
  6. Existing urinary tract infection or bacterial cystitis
  7. Clinically significant and unexplained elevated liver or renal function tests
  8. Women who are pregnant or lactating
  9. Severe cardiovascular disease
  10. History of malignancy of other organ system within past 5 years (except treated basal cell carcinoma or squamous cell carcinoma of the skin)
  11. Subjects who cannot hold instillation for 1 hour
  12. Subjects who cannot tolerate intravesical dosing or intravesical surgical manipulation
  13. Intravesical therapy within 6 weeks of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01687244

United States, Colorado
The Urology Center of Colorado
Denver, Colorado, United States, 80211
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University
St. Louis, Missouri, United States, 63110
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
United States, South Carolina
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States, 29572
United States, Texas
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
Baylor College of Medicine
Houston, Texas, United States, 77030
MD Anderson Cancer Center
Houston, Texas, United States, 77030
The University of Texas Health Science Center
San Antonio, Texas, United States, 78229
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
FKD Therapies Oy
Study Chair: Colin Dinney, MD M.D. Anderson Cancer Center
  More Information

No publications provided

Responsible Party: FKD Therapies Oy Identifier: NCT01687244     History of Changes
Other Study ID Numbers: rAd-IFN-CS-002
Study First Received: September 6, 2012
Last Updated: February 6, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by FKD Therapies Oy:
BCG Refractory Superficial Bladder Cancer
transitional cell carcinoma of the bladder
superficial non-muscle invasive tumor
Interferon alpha2b

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms processed this record on March 03, 2015